In a recent development, a federal judge in New York has rejected Incyte Corp.’s stance concerning its interpretation of a key drug commercialization contract involved in a royalties dispute with Novartis Pharma AG. This decision comes in the context of ongoing litigation, with a jury trial set for next month. The disagreement centers on the differing interpretations of contractual terms that are critical to the distribution of royalties between the two pharmaceutical companies. The judge’s decision implies that the case will proceed to trial, where the nuances of the contract will be further examined.
For more details on the forthcoming proceedings and the implications for both Incyte and Novartis, you can refer to the complete article from Law360.